JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks

J.P. Morgan has reinstated coverage on 14 major biotechnology companies, signaling growing confidence that the biotech sector is entering a transformative growth phase driven by stronger pipelines, expanding commercial portfolios, and improving profitability.

According to the investment bank, several leading biotech companies are now approaching sustained earnings growth as successful clinical developments increasingly translate into profitable businesses. Analysts noted that many firms are moving beyond reliance on a single drug and are building diversified product portfolios capable of supporting long-term revenue expansion.

J.P. Morgan assigned Overweight ratings to several biotech stocks, including Vertex Pharmaceuticals, Alnylam Pharmaceuticals, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis Pharmaceuticals, BioMarin Pharmaceutical, and Mirum Pharmaceuticals. Meanwhile, the bank maintained Neutral ratings on BioNTech, Incyte, and Halozyme Therapeutics, while initiating an Underweight rating on Moderna.

Vertex Pharmaceuticals was highlighted as one of the strongest biotech investment opportunities. Analysts pointed to the company’s expansion beyond cystic fibrosis into kidney disease treatments and pain management therapies, setting a price target of $515. Alnylam Pharmaceuticals also received strong support with a $420 target, fueled by rapid growth of its Amvuttra franchise and improving operating margins.

BeOne Medicines earned praise for continued momentum surrounding Brukinsa and increasing operational efficiency. United Therapeutics was recognized for strong Tyvaso demand in idiopathic pulmonary fibrosis and the future potential of ralinepag in pulmonary arterial hypertension.

J.P. Morgan also identified Insmed as an attractive biotech stock after its recent market pullback, forecasting significant growth from Brinsupri and the company’s TPIP pipeline. Ascendis Pharma was viewed positively due to the strong commercial launch of Yorvipath, which analysts expect to accelerate profitability in the coming quarters.

On the bearish side, analysts warned that Moderna’s recent stock rally may already reflect optimism tied to its cancer vaccine program, while persistent cash burn remains a key concern. BioNTech was described as lacking near-term growth catalysts despite its sizable cash reserves and expanding oncology pipeline.

The bank emphasized that the biotechnology sector is entering a new era marked by stronger margins, broader therapeutic reach, and multiple upcoming clinical catalysts. Investors are expected to closely monitor major oncology readouts and cardiovascular outcomes trials later this year, which could significantly impact biotech stock performance and sector sentiment throughout 2026.